Bank of Stockton Raises Holdings in Sanofi (NASDAQ:SNY)

Bank of Stockton boosted its stake in Sanofi (NASDAQ:SNY) by 6.5% during the first quarter, Holdings Channel.com reports. The firm owned 6,657 shares of the company’s stock after buying an additional 406 shares during the period. Bank of Stockton’s holdings in Sanofi were worth $369,000 at the end of the most recent quarter.

Other large investors have also bought and sold shares of the company. Price T Rowe Associates Inc. MD grew its holdings in shares of Sanofi by 88.5% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 10,843,682 shares of the company’s stock worth $522,991,000 after purchasing an additional 5,091,304 shares during the last quarter. Raymond James Financial Inc. purchased a new stake in Sanofi during the 4th quarter valued at $135,933,000. Boston Partners increased its position in shares of Sanofi by 86.4% in the fourth quarter. Boston Partners now owns 5,396,531 shares of the company’s stock valued at $260,607,000 after acquiring an additional 2,501,073 shares during the period. Magnetar Financial LLC increased its position in shares of Sanofi by 104.3% in the fourth quarter. Magnetar Financial LLC now owns 3,340,317 shares of the company’s stock valued at $161,103,000 after acquiring an additional 1,705,148 shares during the period. Finally, Point72 Asset Management L.P. raised its stake in shares of Sanofi by 969.6% during the fourth quarter. Point72 Asset Management L.P. now owns 950,649 shares of the company’s stock valued at $45,850,000 after acquiring an additional 861,770 shares during the last quarter. 14.04% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

SNY has been the topic of several recent analyst reports. Guggenheim reissued a “buy” rating on shares of Sanofi in a research note on Tuesday, June 3rd. BNP Paribas started coverage on Sanofi in a research note on Tuesday, April 15th. They set an “outperform” rating and a $65.00 target price on the stock. Morgan Stanley set a $56.00 price target on Sanofi in a research note on Monday, June 2nd. Hsbc Global Res raised shares of Sanofi to a “strong-buy” rating in a research report on Monday, April 28th. Finally, The Goldman Sachs Group assumed coverage on shares of Sanofi in a report on Friday, March 21st. They issued a “neutral” rating and a $65.00 price objective for the company. Three investment analysts have rated the stock with a hold rating, three have issued a buy rating and three have given a strong buy rating to the company’s stock. Based on data from MarketBeat, Sanofi currently has a consensus rating of “Buy” and an average target price of $61.50.

Sanofi Price Performance

SNY opened at $47.80 on Thursday. The company has a current ratio of 1.37, a quick ratio of 0.69 and a debt-to-equity ratio of 0.16. The company has a market cap of $117.23 billion, a price-to-earnings ratio of 17.07, a price-to-earnings-growth ratio of 1.00 and a beta of 0.50. The stock has a fifty day simple moving average of $51.06 and a two-hundred day simple moving average of $52.00. Sanofi has a 12-month low of $45.80 and a 12-month high of $60.12.

Sanofi (NASDAQ:SNY) last released its earnings results on Thursday, April 24th. The company reported $0.94 EPS for the quarter, topping the consensus estimate of $0.90 by $0.04. Sanofi had a return on equity of 17.15% and a net margin of 14.56%. The business had revenue of $10.41 billion for the quarter, compared to the consensus estimate of $9.79 billion. During the same period in the previous year, the company posted $1.78 earnings per share. The company’s revenue for the quarter was down 11.0% compared to the same quarter last year. Research analysts predict that Sanofi will post 4.36 earnings per share for the current fiscal year.

Sanofi Increases Dividend

The business also recently declared an annual dividend, which was paid on Thursday, June 12th. Stockholders of record on Friday, May 9th were issued a dividend of $2.0369 per share. This represents a dividend yield of 3.1%. The ex-dividend date was Friday, May 9th. This is an increase from Sanofi’s previous annual dividend of $1.48. Sanofi’s dividend payout ratio (DPR) is presently 57.14%.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.